Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3826-3842
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3826
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3826
Criteria (city, country, reference) | Tumor number | Tumor diameter (cm) | Additional criteria | Overall survivalwithin criteria | |
Hong Kong, China[20] | 1 | ≤ 6.5 | No diffuse type, | 3 yr | 78% |
≤ 3 | ≤ 4.5 | no vascular invasion | 5 yr | 66% | |
Hangzhou, China[21] | NC | Total ≤ 8 | Histopathologic grade I or II with AFP ≤ 400 ng/dL if tumor > 8 cm | 3 yr | 70.7% |
5 yr | 70.7% | ||||
Seoul (AMC), Korea[22] | ≤ 6 | ≤ 5 | No gross vascular invasion | 3 yr | 87.5% |
5 yr | 81.6% | ||||
Seoul (CMC), Korea[23] | ≤ 7 | ≤ 7 | NC | 5 yr | 86.3% |
Tokyo, Japan[24] | ≤ 5 | ≤ 5 | NC | 3 yr | 82% |
5 yr | 75% | ||||
Kyoto, Japan[25] | ≤ 10 | ≤ 5 | PIVKA-II ≤ 400 mAU/mL | 5 yr | 87% |
- Citation: Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: An Eastern perspective. World J Gastroenterol 2015; 21(13): 3826-3842
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3826.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3826